Skip to main content
Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review

Fig. 4

Distribution of CHR status among patients currently receiving HU and patients who discontinued HU. ELN European LeukemiaNet, HU hydroxyurea. CHR status was determined per ELN response criteria. ELN response criteria are based on the following: levels of Hct, platelet count, WBC count, spleen size, and disease symptoms (pruritus, angina, headache) [9]

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us